Literature DB >> 17035335

The betaretrovirus Mason-Pfizer monkey virus selectively excludes simian APOBEC3G from virion particles.

Brian P Doehle1, Hal P Bogerd, Heather L Wiegand, Nolwenn Jouvenet, Paul D Bieniasz, Eric Hunter, Bryan R Cullen.   

Abstract

The APOBEC3 protein family can constitute a potent barrier to the successful infection of mammalian species by retroviruses. Therefore, any retrovirus that has evolved the ability to replicate in a given animal must have developed mechanisms that allow it to avoid or inhibit the APOBEC3 proteins expressed in that animal. Here, we demonstrate that Mason-Pfizer monkey virus (MPMV) is resistant to inhibition by the APOBEC3G protein expressed in its normal host, the rhesus macaque, but highly susceptible to inhibition by murine APOBEC3 (mA3). MPMV virion particles fail to package rhesus APOBEC3G (rA3G), and MPMV Gag binds rA3G poorly in coexpressing cells. In contrast, MPMV virions package mA3 efficiently and MPMV Gag-mA3 complexes are readily detected. Moreover, mA3, but not rA3G, partially colocalizes with MPMV Gag in the cytoplasm of coexpressing cells. Previously, we have demonstrated that murine leukemia virus also escapes inhibition by APOBEC3 proteins by avoiding virion incorporation of its cognate APOBEC3 protein, mA3, yet is inhibited by primate APOBEC3G proteins, which it packages effectively (B. P. Doehle, A. Schäfer, H. L. Wiegand, H. P. Bogerd, and B. R. Cullen, J. Virol. 79:8201-8207, 2005). The finding that two essentially unrelated beta- and gammaretroviruses use similar mechanisms to escape inhibition by the APOBEC3 proteins found in their normal host species suggests that the selective exclusion of APOBEC3 proteins from virion particles may be a general mechanism used by simple mammalian retroviruses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035335      PMCID: PMC1676301          DOI: 10.1128/JVI.01600-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.

Authors:  Heather L Wiegand; Brian P Doehle; Hal P Bogerd; Bryan R Cullen
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

2.  APOBEC3G incorporation into human immunodeficiency virus type 1 particles.

Authors:  Véronique Zennou; David Perez-Caballero; Heinrich Göttlinger; Paul D Bieniasz
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

3.  Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.

Authors:  Alexandra Schäfer; Hal P Bogerd; Bryan R Cullen
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

4.  The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.

Authors:  Silvestro G Conticello; Reuben S Harris; Michael S Neuberger
Journal:  Curr Biol       Date:  2003-11-11       Impact factor: 10.834

5.  APOBEC3G targets specific virus species.

Authors:  Masayuki Kobayashi; Akifumi Takaori-Kondo; Keisuke Shindo; Aierken Abudu; Keiko Fukunaga; Takashi Uchiyama
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

6.  APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.

Authors:  Mark T Liddament; William L Brown; April J Schumacher; Reuben S Harris
Journal:  Curr Biol       Date:  2004-08-10       Impact factor: 10.834

7.  Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.

Authors:  Yong-Hui Zheng; Dan Irwin; Takeshi Kurosu; Kenzo Tokunaga; Tetsutaro Sata; B Matija Peterlin
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 matrix inhibits and confers cooperativity on gag precursor-membrane interactions.

Authors:  David Perez-Caballero; Theodora Hatziioannou; Juan Martin-Serrano; Paul D Bieniasz
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

10.  Cytidine deamination of retroviral DNA by diverse APOBEC proteins.

Authors:  Kate N Bishop; Rebecca K Holmes; Ann M Sheehy; Nicholas O Davidson; Soo-Jin Cho; Michael H Malim
Journal:  Curr Biol       Date:  2004-08-10       Impact factor: 10.834

View more
  21 in total

1.  Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin.

Authors:  Nolwenn Jouvenet; Stuart J D Neil; Maria Zhadina; Trinity Zang; Zerina Kratovac; Youngnam Lee; Matthew McNatt; Theodora Hatziioannou; Paul D Bieniasz
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

Review 2.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

3.  Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.

Authors:  John S Albin; Guylaine Haché; Judd F Hultquist; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

4.  Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G.

Authors:  Guylaine Haché; Truus E M Abbink; Ben Berkhout; Reuben S Harris
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

5.  Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation.

Authors:  Hal P Bogerd; Bryan R Cullen
Journal:  RNA       Date:  2008-05-02       Impact factor: 4.942

6.  Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.

Authors:  Hal P Bogerd; Rebecca L Tallmadge; J Lindsay Oaks; Susan Carpenter; Bryan R Cullen
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

7.  Apobec 3G efficiently reduces infectivity of the human exogenous gammaretrovirus XMRV.

Authors:  Kristin Stieler; Nicole Fischer
Journal:  PLoS One       Date:  2010-07-23       Impact factor: 3.240

8.  Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins.

Authors:  Heather L Wiegand; Bryan R Cullen
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

9.  Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G.

Authors:  Guylaine Haché; Keisuke Shindo; John S Albin; Reuben S Harris
Journal:  Curr Biol       Date:  2008-05-22       Impact factor: 10.834

Review 10.  APOBEC proteins and intrinsic resistance to HIV-1 infection.

Authors:  Michael H Malim
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-03-12       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.